December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

36.34 -0.23 (-0.63%)
Delayed Quote Updated: 11:41 AM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
From Roivant Sciences
Via GlobeNewswire
News headline image
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
From Roivant Sciences
Via GlobeNewswire
News headline image
Analyst Ratings for Roivant Sciences ↗
 
Via Benzinga
News headline image
8 Analysts Have This to Say About Roivant Sciences ↗
 
Via Benzinga
News headline image
Roivant Sciences Earnings Preview ↗
 
Via Benzinga
News headline image
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
From Roivant Sciences
Via GlobeNewswire
News headline image
Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today? ↗
Roivant Sciences Ltd (NASDAQ: ROIV) and Priovant's Phase 2 study of oral brepocitinib in moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus (SLE)  
Via Benzinga
News headline image
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
What 8 Analyst Ratings Have To Say About Roivant Sciences ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 13, 2023 ↗
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
News headline image
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
From Roivant Sciences
Via GlobeNewswire
News headline image
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy ↗
The market's dour reaction to Roivant Sciences' latest deal doesn't add up. 
Via The Motley Fool
News headline image
FSR Stock Alert: What to Know as Fisker Drops Prices ↗
Fisker stock is on the move Monday as investors in FSR react to news of a price drop for one version of the company's Ocean EV. 
Via InvestorPlace
News headline image
PINS Stock Pops as Stifel Upgrades Pinterest ↗
Pinterest stock is getting a boost on Monday after a Stifel analyst upgraded PINS to a 'buy' rating and increasing its price target. 
Via InvestorPlace
News headline image
Why Is Roivant Sciences (ROIV) Stock Up Today? ↗
ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates. 
Via InvestorPlace
News headline image
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space ↗
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases. 
Via Investor's Business Daily
News headline image
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal ↗
Roche Holding AG (OTC: RHHBY) inked a deal to acquire  
Via Benzinga
News headline image
Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket ↗
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set... 
Via Benzinga
News headline image
Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
From Roivant Sciences
Via GlobeNewswire
News headline image
Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer
From Covant Therapeutics
Via GlobeNewswire
News headline image
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble. ↗
The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck. 
Via Investor's Business Daily
News headline image
3 No-Brainer Growth Stocks to Buy in October ↗
These three top mid-cap stocks could be poised for a long-tailed growth spurt. 
Via The Motley Fool
News headline image
Why Immunovant Stock Is Bolting Higher Today ↗
The company may have best-in-class autoimmune disease therapy under its roof. 
Via The Motley Fool
News headline image
Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday ↗
Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market... 
Via Benzinga
News headline image
Roivant Stock Price Outlook: Strong Pipeline Is A Catalyst ↗
Roivant Sciences has 12 drugs in its pipeline. The company’s Immunovant subsidiary reported strong results for its drug. Roivant is in talks with Roche to sell its Chron’s disease for $7 billion. 
Via Talk Markets
News headline image
Why Shares of Immunovant Are Soaring on Tuesday ↗
Immunovant sees strong potential for an autoimmune disorder therapy. 
Via The Motley Fool
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.